Drug
Elritercept
Elritercept: highest development phase Phase 3, developed by Takeda. 3 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Takeda
Trials
| Drug | Phase | Indication |
|---|---|---|
| Elritercept NCT06499285 | Phase 3 | Myelodysplastic Syndromes |
| Elritercept NCT07422480 | Phase 3 | Myelodysplastic Syndrome |
| Elritercept NCT07623161 | Phase 3 | Myelofibrosis |
Latest
No recent events.
Follow Elritercept on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.